Also known as sirolimus or Rapamune, rapamycin inhibits the activity of a protein called mTOR, which helps regulate cell growth and metabolism. Suppressing mTOR seems to weaken inflammation and ...

The drug blocks the activity of a protein known as mammalian target of rapamycin (mTOR), which promotes proliferation through the activation of proteins such as S6 kinase. Although the mTOR ...

Fifth issued patent in the U.S. for QTORIN™ rapamycin with anticipated patent life extending into 2038 QTORIN™ rapamycin has ...

In particular, the mechanistic target of rapamycin (mTOR) pathway has been tied to multiple age-related chronic disease processes, such as declining immune function, diminishing bone mineral ...

The mTOR signaling pathway is upregulated in a variety of solid and hematologic tumors. Two inhibitors of this pathway, temsirolimus and everolimus, have been approved for use in metastatic RCC.

About Microcystic Lymphatic Malformations Microcystic LMs are a rare, chronically debilitating genetic disease caused by dysregulation of the phosphatidylinositol 3-kinase (PI3K)/mammalian target of ...

Although recommended, many patients with metastatic clear cell RCC still don’t receive immune checkpoint inhibitor-based combinations as first-line treatment.

Palvella Therapeutics (PVLA) announced that the United States Patent and Trademark Office, USPTO, issued patent No. 12,268,673 for claims ...

The granted patent “Anhydrous Compositions of mTOR Inhibitors and Methods of Use” broadens protection for QTORIN™ rapamycin and the conditions related to its use in clinical indications ...